title: [Waldenström's macroglobulinemia].
abstract: Waldenström's macroglobulinemia (WM) is a B-cell disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells, along with the presence of an IgM monoclonal gammopathy in the blood. WM remains incurable with a median of 8-year of overall survival for patients with symptomatic WM. Treatment is postponed for asymptomatic patients and progressive anemia is the most common indication for initiation of treatment. The main therapeutic options include alkylating agents, nucleoside analogues, and rituximab, either alone or in combination. Studies involving new combination chemotherapy are ongoing and preliminary results are encouraging. However, there are several limitations to these approaches. The complete response rate is low and the treatment free survival is short in many patients, no specific agent or regimen has been shown to be superior to another, and no treatment has been specifically approved for WM. As such, new therapeutic agents are needed for the treatment of WM. In ongoing efforts, we and others have sought to exploit advances made in the understanding of the biology of WM so as to better target therapeutics for this malignancy. These efforts have led to the development of proteasome inhibitors as bortezomib, several Akt/mTor inhibitors, such as perifosine and Rad001. Many other agents and monoclonal antibodies are currently being tested in clinical trials and seem promising. This article provides an update of the current preclinical studies and clinical efforts for the development of novel agents in the treatment of WM.
authors.affiliation: Service d'hématologie-immunologie-cytogénétique, centre hospitalier, CHR, avenue Désandrouin, 59300 Valenciennes, France.
authors.forename: S
authors.initials: S
authors.lastname: Poulain
authors.forename: M
authors.initials: M
authors.lastname: Wemeau
authors.forename: S
authors.initials: S
authors.lastname: Balkaran
authors.forename: B
authors.initials: B
authors.lastname: Hivert
authors.forename: A
authors.initials: A
authors.lastname: Hautecoeur
authors.forename: J
authors.initials: J
authors.lastname: Rossignol
authors.forename: J
authors.initials: J
authors.lastname: Fernandez
authors.forename: A
authors.initials: A
authors.lastname: Daudignon
authors.forename: C
authors.initials: C
authors.lastname: Roumier
authors.forename: V
authors.initials: V
authors.lastname: Soenen
authors.forename: P
authors.initials: P
authors.lastname: Lepelley
authors.forename: J-L
authors.initials: JL
authors.lastname: Lai
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: X
authors.initials: X
authors.lastname: Leleu
mesh_terms: D000368:Aged; D000740:Anemia / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D009705:Nucleosides / Q000008:administration & dosage; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives; D011379:Prognosis; D011480:Protease Inhibitors / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D000069283:Rituximab; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018906:Antineoplastic Agents, Alkylating; D001897:Boronic Acids; D009705:Nucleosides; D011480:Protease Inhibitors; D011719:Pyrazines; D010767:Phosphorylcholine; C105905:perifosine; D000069283:Rituximab; D000069286:Bortezomib